OxiGene Inc (OXGN)

0.71
0.06 9.23
NASDAQ : Health Care
Prev Close 0.65
Open 0.67
Day Low/High 0.67 / 0.72
52 Wk Low/High 0.49 / 1.40
Volume 135.33K
Avg Volume 534.20K
Exchange NASDAQ
Shares Outstanding 26.54M
Market Cap 18.58M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OXiGENE Announces Name Change To Mateon Therapeutics

OXiGENE Announces Name Change To Mateon Therapeutics
OXiGENE Receives U.S. Orphan Drug Designation for CA4P To Treat Glioma

OXiGENE Receives U.S. Orphan Drug Designation for CA4P To Treat Glioma
OXiGENE Announces Results Of Phase 2 Study Of CA4P In Recurrent Ovarian Cancer Published In Journal Of Clinical Oncology

OXiGENE Announces Results Of Phase 2 Study Of CA4P In Recurrent Ovarian Cancer Published In Journal Of Clinical Oncology

OXiGENE Reports First Quarter 2016 Financial Results

OXiGENE Reports First Quarter 2016 Financial Results

Oxigene Receives Fast Track Designation From U.S. FDA For CA4P

Oxigene Receives Fast Track Designation From U.S. FDA For CA4P

OXiGENE Reports 2015 Financial Results

OXiGENE Reports 2015 Financial Results

OXiGENE Receives European Orphan Drug Designation For CA4P To Treat Neuroendocrine Tumors

OXiGENE Receives European Orphan Drug Designation For CA4P To Treat Neuroendocrine Tumors

OXiGENE Appoints Dr. Simon Pedder To Board Of Directors

OXiGENE Appoints Dr. Simon Pedder To Board Of Directors

OXiGENE Announces Upcoming Presentation At The BIO-CEO Conference And Provides Business Update

OXiGENE Announces Upcoming Presentation At The BIO-CEO Conference And Provides Business Update

OXiGENE Receives U.S. Orphan Drug Designation For CA4P To Treat Neuroendocrine Tumors

OXiGENE Receives U.S. Orphan Drug Designation For CA4P To Treat Neuroendocrine Tumors

OXiGENE Receives European Orphan Drug Designation For OXi4503 To Treat Acute Myeloid Leukemia

OXiGENE Receives European Orphan Drug Designation For OXi4503 To Treat Acute Myeloid Leukemia

OXiGENE Reports Third Quarter 2015 Financial Results

OXiGENE Reports Third Quarter 2015 Financial Results

OXiGENE Announces Positive Initial Data From Phase 1b Study Of CA4P In Combination With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer

OXiGENE Announces Positive Initial Data From Phase 1b Study Of CA4P In Combination With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer

-- Based on Positive Safety Data and Preliminary Signs of Efficacy, Study Expected to Advance to Phase 2 Portion in Early 2016 --

OXiGENE Announces Initiation Of Phase 1b/2 Clinical Trial Of OXi4503 In Acute Myeloid Leukemia

OXiGENE Announces Initiation Of Phase 1b/2 Clinical Trial Of OXi4503 In Acute Myeloid Leukemia

OXiGENE Announces Interim Phase 2 Data For Lead Clinical Candidate CA4P (fosbretabulin) In Neuroendocrine Tumors

OXiGENE Announces Interim Phase 2 Data For Lead Clinical Candidate CA4P (fosbretabulin) In Neuroendocrine Tumors

OXiGENE To Present At The 14th Annual BIO Investor Forum

OXiGENE To Present At The 14th Annual BIO Investor Forum

OXiGENE Announces Plans To Advance CA4P (Fosbretabulin) In Two Late-Stage Clinical Trials

OXiGENE Announces Plans To Advance CA4P (Fosbretabulin) In Two Late-Stage Clinical Trials

OXiGENE Reports Second Quarter 2015 Financial Results

OXiGENE Reports Second Quarter 2015 Financial Results

OXiGENE To Host Second Quarter Financial Results Conference Call And Webcast

OXiGENE To Host Second Quarter Financial Results Conference Call And Webcast

OXiGENE Appoints Matthew M. Loar As Chief Financial Officer

OXiGENE Appoints Matthew M. Loar As Chief Financial Officer

Adds Broad Finance and Operating Experience to Company's New Leadership

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

OXiGENE (OXGN) shares are rising after the company announced that the FDA gave preliminary approval for the method of its phase 3 cancer treatment study.

OXiGENE Receives Guidance From FDA Supporting Phase 3 Trial Of Fosbretabulin/Bevacizumab Combination In Platinum-Resistant Ovarian Cancer

OXiGENE Receives Guidance From FDA Supporting Phase 3 Trial Of Fosbretabulin/Bevacizumab Combination In Platinum-Resistant Ovarian Cancer

OXiGENE Announces Issuance Of U.S. Patent For OXi4503 In Acute Myeloid Leukemia

OXiGENE Announces Issuance Of U.S. Patent For OXi4503 In Acute Myeloid Leukemia

OXiGENE Appoints Bill Schwieterman, M.D., As President And Chief Executive Officer

OXiGENE Appoints Bill Schwieterman, M.D., As President And Chief Executive Officer

Dai Chaplin Becomes Chief Scientific Officer

OXiGENE Reports First Quarter 2015 Financial Results

OXiGENE Reports First Quarter 2015 Financial Results

Strengthened Cash Position; Fosbretabulin and OXi4503 Clinical Programs Advancing

OXiGENE Announces First Quarter Financial Results Conference Call And Webcast

OXiGENE Announces First Quarter Financial Results Conference Call And Webcast

OXiGENE Announces Participation In Upcoming Investor And Medical Conferences

OXiGENE Announces Participation In Upcoming Investor And Medical Conferences

OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering

OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering

OXiGENE Reports Financial Results For 2014

OXiGENE Reports Financial Results For 2014

OXiGENE Announces 2014 Financial Results Conference Call And Webcast

OXiGENE Announces 2014 Financial Results Conference Call And Webcast

Load More

From Our Partners

OXiGENE Announces Changes to Board of Directors
Benzinga

ZYBRESTAT Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer
Benzinga

Morning Market Movers
Benzinga

UPDATE 1-Oxigene reports positive data on cancer drug
Reuters

UPDATE 1-Oxigene says auditors raise going concern doubts
Reuters

UPDATE 1-Oxigene to cut half the jobs, sees Q1 charge
Reuters
Get the Investing Edge.
Join Jim Cramer's Members-Only Investing Club
Become an Action Alerts PLUS member to learn from the pros how to invest wisely and build a customized portolio of blue chip stocks.
LEARN MORE
Uncover New Investment Opportunities With Our Team of Experts
Jim Cramer and his army of Wall Street pros serve up new trading ideas and in-depth market analysis every day.
LEARN MORE

Watchlist